Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complexhaplo-identical non-myeloablative hematopoietic cell transplantation

Cytotherapy

Volumn 13, Issue 10, 2011, Pages 1269-1280

  Chen, Yun ^a,d   Fukuda, Takahiro ^a   Thakar, Monica S ^a,b   Kornblit, Brian T ^a   Storer, Barry E ^a,c   Santos, Erlinda B ^a   Storb, Rainer ^a,c   Sandmaier, Brenda M ^a,c  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d SHANDONG UNIVERSITY   (China)

Author keywords

animal model; cytotoxic T lymphocyte antigen 4 immunoglobulin; haplo identical transplantation; non myeloablative transplantation

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; RECOMBINANT ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD DONOR; CD3+ T LYMPHOCYTE; CELL ACTIVITY; CELL ASSAY; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG EFFECT; ENGRAFTMENT; EXPERIMENTAL DOG; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MAXIMUM PLASMA CONCENTRATION; MIXED LEUKOCYTE CULTURE; NATURAL KILLER CELL; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RADIATION DOSE; STEM CELL MOBILIZATION; T LYMPHOCYTE ACTIVATION; WHOLE BODY RADIATION;

EID: 80054729067     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.586997     Document Type: Article

References (54)

1. Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance [erratum appears in Immunol Rev. 2004;197:243]. Immunol Rev. 2003;196:85-108. (Pubitemid 37468106)
2. McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 costimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev. 1998;165:231-47. (Pubitemid 28524215)
3. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992; 356:607-9.
4. Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei RQ, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA. 1992;89:11102-5.
5. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561-9.
6. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol. 1995;155:4521-4.
7. Judge TA, Wu Z, Zheng XG, Sharpe AH, Sayegh MH, Turka LA. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol. 1999;162:1947-51. (Pubitemid 29288810)
8. Loughran TP Jr., Deeg HJ, Storb R. Morphologic and phenotypic analysis of canine natural killer cells: Evidence for T-cell lineage. Cell Immunol. 1985;95:207-17. (Pubitemid 16222349)
9. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science. 1992; 257:789-92.
10. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specifi c transfusion. J Exp Med. 1993;178:1801 - 6. (Pubitemid 23318461)
11. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation. 1994;57:1701-6. (Pubitemid 24206406)
12. Wallace PM, Johnson JS, Macmaster JF, Kennedy KA, Gladstone P, Linsley PS. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation. 1994;58: 602-10. (Pubitemid 24289853)
13. Yin DP, Sankary HN, Williams J, Krieger N, Fathman CG. Induction of tolerance to small bowel allografts in highresponder rats by combining anti-CD4 with CTLA4Ig. Transplantation. 1996;62:1537-9. (Pubitemid 27009906)
14. Levisetti MG, Padrid PA, Szot GL, Mittal N, Meehan SM, Wardrip CL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol. 1997;159:5187-91. (Pubitemid 127470041)
15. Shirasugi N, Akiyama Y, Aramaki O, Shibutani S, Matsumoto K, Bashuda H, et al. Role of the CTLA4 pathway in hyporesponsiveness induced by intratracheal delivery of alloantigen. Transplantation. 2003;75:1636-9. (Pubitemid 36629142)
16. Foster RD, Pham S, Li S, Aitouche A. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. Transplantation. 2003;76:988-94. (Pubitemid 37186033)
17. Ibrahim S, Jakobs F, Kittur D, Hess A, Linsley PS, Sanfi lippo F, et al. CTLA4Ig inhibits alloantibody responses to repeated blood transfusions. Blood. 1996;88:4594-600.
18. Speiser DE, Bachmann MF, Shahinian A, Mak TW, Ohashi PS. Acute graft-versus-host disease without costimulation via CD28. Transplantation. 1997;63:1042-4. (Pubitemid 27173036)
19. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048-54. (Pubitemid 27172593)
20. Storb R, Yu C, Zaucha JM, Deeg HJ, Georges G, Kiem H-P, et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood. 1999;94:2523-9. (Pubitemid 29467702)
21. Fukuda T, Kerbauy FR, Gooley T, Santos EB, Storb R, Sandmaier BM. Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and nonmyeloablative conditioning in a preclinical canine model. Transplantation. 2006;82:332-9. (Pubitemid 44223031)
22. Sandmaier BM, Storb R, Appelbaum FR, Gallatin WM. An antibody that facilitates hematopoietic engraftment recognizes CD44. Blood. 1990;76:630-5. (Pubitemid 20251835)
23. Sandmaier BM, Storb R, Bennett KL, Appelbaum FR, Santos EB. Epitope specifi city of CD44 for monoclonal antibody dependent facilitation of marrow engraftment in a canine model. Blood. 1998;91:3494-502. (Pubitemid 28193904)
24. Tan PHS, Santos EB, Rossbach HC, Sandmaier BM. Enhancement of natural killer activity by an antibody to CD44. J Immunol. 1993;150:812-20. (Pubitemid 23133661)
25. Tan PH, Liu Y, Santos EB, Sandmaier BM. Mechanisms of enhancement of natural killer activity by an antibody to CD44: Increase in conjugate formation and release of tumor necrosis factor á Cell Immunol. 1995;164:255-64.
26. Tan PH, Sandmaier BM, Stayton PS. Characterization of an anti-CD44 single-chain F V antibody that stimulates natural killer cell activity and induces TNF á release. Immunol Invest. 1995;24:907-26.
27. Wagner JL, Burnett RC, DeRose SA, Francisco LV, Storb R, Ostrander EA. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation. 1996;62:876-7. (Pubitemid 26332860)
28. Wagner JL, Burnett RC, Works JD, Storb R. Molecular analysis of DLA-DRBB1 polymorphism. Tissue Antigens. 1996;48:554-61. (Pubitemid 27007295)
29. Wagner JL, Works JD, Storb R. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. Tissue Antigens. 1998;52:397-401. (Pubitemid 28467017)
30. Raff RF, Deeg HJ, Farewell VT, DeRose S, Storb R. The canine major histocompatibility complex. Population study of DLA-D alleles using a panel of homozygous typing cells. Tissue Antigens. 1983;21:360-73.
31. Storb R, Raff RF, Graham T, Appelbaum FR, Deeg HJ, Schuening FG, et al. Marrow toxicity of fractionated versus single dose total body irradiation is identical in a canine model. Int J Radiat Oncol Biol Phys. 1993;26:275-83. (Pubitemid 23156974)
32. Zaucha JM, Zellmer E, Georges G, Little M-T, Storb R, Storer B, et al. G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplant. 2001;7:613-9. (Pubitemid 33130594)
33. Sandmaier BM, Storb R, Santos EB, Krizanac-Bengez L, Lian T, McSweeney PA, et al. Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood. 1996;87:3508-13. (Pubitemid 26115385)
34. Lee R, Storb R, Little M-T, Joslyn A, Spector M, Kuhr CS. Percutaneous central dual-lumen catheter for apheresis in the canine. J Invest Surg. 2002;15:337-41. (Pubitemid 36104733)
35. Deeg HJ, Storb R. Canine marrow transplantation models. Curr Topics Vet Res. 1994;1:103-14.
36. Ladiges WC, Storb R, Thomas ED. Canine models of bone marrow transplantation. Lab Anim Sci. 1990;40:11-5.
37. Moore PF, Rossitto PV, Danilenko DM, Wielenga JJ, Raff RF, Severns E. Monoclonal antibodies specifi c for canine CD4 and CD8 defi ne functional T-lymphocyte subsets and high density expression of CD4 by canine neutrophils. Tissue Antigens. 1992;40:75-85.
38. Barsoukov AA, Moore PF, Storb R, Santos EB, Sandmaier BM. The use of an anti-TCR á ǎ monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. Transplantation. 1999;67:1329-35. (Pubitemid 29252408)
39. Sandmaier BM, Schuening FG, Bianco JA, Rosenman SJ, Bernstein I, Goehle S, et al. Biochemical characterization of a unique canine myeloid antigen. Leukemia. 1991;5:125-30.
40. Denkers E, Badger CC, Ledbetter JA, Bernstein ID. Infl uence of antibody isotype on passive serotherapy of lymphoma. J Immunol. 1985;135:2183-6. (Pubitemid 16240056)
41. Jacobsen CN, Aasted B, Broe MK, Petersen JL. Reactivities of 20 anti-human monoclonal antibodies with leucocytes from ten different animal species. Vet Immunol Immunopath. 1993;39:461-6. (Pubitemid 24023355)
42. Yu C, Ostrander E, Bryant E, Burnett R, Storb R. Use of (CA) n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation. 1994;58:701-6. (Pubitemid 24317770)
43. Raff RF, Sandmaier BM, Graham T, Loughran TP Jr., Pettinger M, Storb R. 'Resistance ' to DLA-nonidentical canine unrelated marrow grafts is unrestricted by the major histocompatibility complex. Exp Hematol. 1994;22:893-7. (Pubitemid 24264759)
44. Raff RF, Deeg HJ, Loughran TP Jr., Graham TC, Aprile JA, Sale GE, et al. Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLAnonidentical donors. Blood. 1986;68:861-8. (Pubitemid 17183844)
45. Storb R, Weiden PL, Graham TC, Lerner KG, Nelson N, Thomas ED. Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran. Evidence for resistance to grafts not associated with DLA and abrogated by antithymocyte serum. Transplantation. 1977;24:349-57.
46. Srinivas NR, Shyu WC, Weiner RS, Tay LK, Greene DS, Barbhaiya RH. Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice. J Pharm Sci. 1995; 84:1488-9.
47. Srinivas NR, Weiner RS, Warner G, Shyu WC, Davidson T, Fadrowski CG, et al. Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. J Pharm Sci. 1996;85:1-4.
48. Lundquist L. Abatacept: A novel therapy approved for the treatment of patients with rheumatoid arthritis. Adv Ther. 2007;24:333-45. (Pubitemid 46988377)
49. Storb R, Raff RF, Appelbaum FR, Schuening F, Sandmaier B, Shulman H, et al. Failure of antithymocyte serum postgrafting to overcome 'resistance ' to DLA-nonidentical canine marrow grafts. Transplantation. 1988;45:236-9. (Pubitemid 18084647)
50. Suzue K, Reinherz EL, Koyasu S. Critical role of NK but not NKT cells in acute rejection of parental bone marrow cells in F1 hybrid mice. Eur J Immunol. 2001;31:3147-52. (Pubitemid 33100506)
51. Larsen CP, Page A, Linzie KH, Russell M, Deane T, Stempora L, et al. An MHC-defi ned primate model reveals signifi cant rejection of bone marrow after mixed chimerism induction despite full MHC matching. Am J Transplant. 2010;10: 2396-409.
52. Montgomery M, Cottler-Fox M. Mobilization and collection of autologous hematopoietic progenitor/stem cells. Clin Adv Hematol Oncol. 2007;5:127-36. (Pubitemid 46455272)
53. Cashen AF, Nervi B, DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Fut Oncol. 2007;3:19-27.
54. Thakar MS, Santos EB, Fricker S, Bridger G, Storb R, Sandmaier BM. Plerixafor-mobilized stem cells alone are capable of inducing early engraftment across the MHC - haploidentical canine barrier. Blood. 2010;115:916-7.